Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Details Narrative)

v3.10.0.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended 60 Months Ended
Dec. 22, 2017
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Dec. 31, 2017
Patent and licensing costs   $ 243,153 $ 172,394 $ 460,813 $ 487,748    
Minimum concentration of risk percent       10.00%      
Deferred setup and organization costs, amortization period       180 months      
Unrecognized tax benefits      
Tax Reform Law [Member]              
Federal corporate tax rate 21.00%            
Income tax reconciliation description The Tax Reform Act reduces the federal corporate tax rate from 35% to 21% effective January 1, 2018            
Theradex Systems, Inc [Member]              
Total estimated clinical costs to be charged to operations             $ 2,233,248
Percentage of clinical trial service           60.00%  
Percentage of clinical center laboratory cost           40.00%  
Clinical costs charged to operations       $ 0 $ 64,615    
Percentage of research and development costs       0.00% 41.00%